A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by
the exposure of non-tumor cells to cytotoxic agents. Use of molecular targeted drugs, such …

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the
antitumor properties of the humanized anti-human epidermal growth factor receptor 2 …

Antibody-drug conjugates (ADCs) are being developed worldwide with the potential to
revolutionize current cancer treatment strategies. Developing novel theranostic ADCs with …

The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer
validated HER2 as a target for HER2-specific antibody–drug conjugates (ADC). Despite its …

Trastuzumab emtansine (Kadcyla®) was the first antibody-drug conjugate (ADC) approved
by the Food and Drug Administration in 2013 against a solid tumor, and the first ADC to treat …

The conjugation of antibodies with cytotoxic drugs can alter their in vivo pharmacokinetics.
As a result, the careful assessment of the in vivo behavior, and specifically the tumor …

Conventional antibody–drug conjugates (ADC) utilize native surface-exposed lysines or
cysteines on the antibody of interest to conjugate cytotoxic payload. The nonspecific …

The emergence of antibody–drug conjugates (ADC), such as brentuximab vedotin and ado-
trastuzumab emtansine, has led to increased efforts to identify new payloads and develop …

Antibody–drug conjugates (ADCs) are designed to combine the exquisite specificity of
antibodies to target tumor antigens with the cytotoxic potency of chemotherapeutic drugs. In …

Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor
tissue and have significant antitumor efficacy with a wide therapeutic window. DS‐8201a is …